先天性心疾患（CHD）の世界市場レポート 2025年

先天性心疾患（CHD）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.7％で70億5,000万米ドルに成長します。予測期間の成長は、発展途上地域におけるヘルスケアサービスへのアクセス拡大、心臓画像技術における継続的な技術革新、早期発見・早期治療を推進する啓発キャンペーンの高まり、世界の医療費の増加、個別化医療の発展に起因すると考えられます。予測期間における主な動向としては、低侵襲手術技術の採用、遠隔患者モニタリングや診察のための遠隔医療の利用拡大、個別化治療アプローチに対する需要の高まり、機能性と寿命が強化された革新的な埋め込み型デバイスの開発、診断・治療プロセスにおける人工知能と機械学習の統合などが挙げられます。

母体糖尿病の有病率の増加は、今後の先天性心疾患（CHD）市場の拡大を促進すると予想されます。妊娠糖尿病（GDM）としても知られる母体糖尿病は、妊娠前には糖尿病ではなかった女性が妊娠中に発症します。主に、座りがちな生活や食生活の乱れ、出産適齢期の女性の肥満率の上昇など、ライフスタイルの変化によって引き起こされます。母親の血糖値が上昇すると胎児の心臓の発達が妨げられるため、母親の糖尿病は乳児の先天性心疾患（CHD）リスクを高める可能性があります。高いグルコースレベルは赤ちゃんの心臓の正常な形成に影響を与え、CHDの可能性が高くなります。例えば、2023年10月、英国の政府機関である国民保健サービスは、2型糖尿病と診断された女性の妊娠有害転帰が2021年の4.9％から2022年には6.6％に増加したと報告しました。その結果、母親の糖尿病患者数の増加が先天性心疾患（CHD）市場の成長に寄与しています。

先天性心疾患市場の主要企業は、患者の転帰とQOLを高めるために非外科的心臓弁の技術革新を進めています。非外科的心臓弁はトランスカテーテルとも呼ばれ、従来の開心術を行わずに心臓弁膜症を治療する医療機器です。例えば、2023年2月、米国の医療技術企業であるメドトロニック社は、ハーモニー経カテーテル肺動脈弁（TPV）システムを再導入しました。開心術に代わる低侵襲のこのシステムは、先天性心疾患、特に先天性または手術で修復された右室流出路（RVOT）異常を持つ患者に対応します。右側用に設計された最初のFDA承認バルブであり、重度の肺動脈弁逆流患者に非外科的ソリューションを提供します。ハーモニーTPVシステムは、2021年に米国FDAの承認を取得し、自主回収後に再販され、先天性心疾患患者のためのソリューションを前進させるメドトロニックの献身を強調しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界先天性心疾患（CHD） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の先天性心疾患（CHD）市場：成長率分析
• 世界の先天性心疾患（CHD）市場の実績：規模と成長, 2019-2024
• 世界の先天性心疾患（CHD）市場の予測：規模と成長, 2024-2029, 2034F
• 世界先天性心疾患（CHD）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の先天性心疾患（CHD）市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 心臓弁の欠陥
• 心臓壁の欠陥
• 血管の欠陥
• その他のタイプ
• 世界の先天性心疾患（CHD）市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 心電図
• 胸部X線写真
• 心エコー検査
• 経食道心エコー検査
• パルスオキシメトリー
• 運動負荷試験
• 心臓CTスキャンまたは磁気共鳴画像検査（MRI）
• 心臓カテーテル検査
• その他の診断
• 世界の先天性心疾患（CHD）市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• インターベンショナルカーディオロジー
• 心臓手術
• 遠隔医療
• 薬物管理
• ライフスタイルの変更
• 世界の先天性心疾患（CHD）市場：年齢層別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳児
• 子供たち
• 青少年
• 大人
• 世界の先天性心疾患（CHD）市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 診断センター
• 外来手術センター
• 調査・学術機関
• 世界の先天性心疾患（CHD）市場心臓弁欠損の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 大動脈弁狭窄症
• 肺動脈弁狭窄症
• 僧帽弁逸脱症
• 三尖弁欠損症
• 弁逆流
• 世界の先天性心疾患（CHD）市場心臓壁欠損のサブセグメンテーション（種類別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 心房中隔欠損症（ASD）
• 心室中隔欠損症（VSD）
• 房室中隔欠損症（AVSD）
• 左心低形成症候群（HLHS）
• ファロー四徴症（TOF）
• 世界の先天性心疾患（CHD）市場血管欠損の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 大動脈狭窄症
• 動脈管開存症（PDA）
• 肺動脈狭窄
• 大血管転位症（TGA）
• 動脈幹
• 世界の先天性心疾患（CHD）市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単心室欠損症
• エプスタインの異常
• 総肺静脈還流異常症（TAPVR）
• 冠動脈異常
• 肺静脈閉塞症

第7章 地域別・国別分析

• 世界の先天性心疾患（CHD）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の先天性心疾患（CHD）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 先天性心疾患（CHD）市場：競合情勢
• 先天性心疾患（CHD）市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Medtronic Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Siemens Healthineers
• Philips Healthcare
• Roche Diagnostics International Ltd.
• Boston Scientific Corp.
• Laboratory Corporation of America Holdings（LabCorp）
• Terumo Corporation
• Mindray Medical International Limited
• Canon Medical Systems Corporation
• Masimo Corporation
• Neusoft Corp.
• Carestream Health
• Midmark Corporation
• Contec Medical Systems
• Randox Laboratories Ltd.
• Schiller AG

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 先天性心疾患（CHD）市場2029：新たな機会を提供する国
• 先天性心疾患（CHD）市場2029：新たな機会を提供するセグメント
• 先天性心疾患（CHD）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Congenital heart disease (CHD) encompasses a spectrum of birth defects affecting the structure and function of the heart present at birth. These defects may involve abnormalities in the heart walls, valves, arteries, and veins near the heart. Treatment for CHD varies depending on the type and severity of the defect and may include medications, catheter-based interventions, open-heart surgery, or heart transplantation.

The primary types of congenital heart disease (CHD) include heart valve defects, heart wall defects, blood vessel defects, and others. Heart valve defects entail abnormalities or malfunctions in the heart valves, which regulate blood flow within the heart. Diagnosis methods may include electrocardiograms, chest X-rays, echocardiograms, transesophageal echocardiograms, pulse oximetry, exercise stress tests, cardiac computed tomography (CT) scans, magnetic resonance imaging (MRI), cardiac catheterization, among others. Treatment options range from interventional cardiology procedures to cardiac surgery, medication management, telemedicine, and lifestyle modifications. CHD affects individuals across all age groups, including infants, children, adolescents, and adults, who receive treatment in hospitals, clinics, diagnostic centers, ambulatory surgical centers, and research and academic institutions.

The congenital heart disease market research report is one of a series of new reports from The Business Research Company that provides congenital heart disease market statistics, including congenital heart disease industry global market size, regional shares, competitors with a congenital heart disease market share, detailed congenital heart disease market segments, market trends and opportunities, and any further data you may need to thrive in the congenital heart disease industry. This congenital heart disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The congenital heart disease (CHD) market size has grown rapidly in recent years. It will grow from $4.42 billion in 2024 to $4.87 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to the increased prevalence of risk factors such as obesity and smoking, improved diagnostic technologies, expanded geriatric population, heightened awareness campaigns, enhanced reimbursement policies, and increased investment in research and development.

The congenital heart disease (CHD) market size is expected to see strong growth in the next few years. It will grow to $7.05 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to expanding access to healthcare services in developing regions, continuous innovation in cardiac imaging technologies, growing awareness campaigns promoting early detection and treatment, rising healthcare expenditure globally, and the development of personalized medicine. Major trends in the forecast period include adoption of minimally invasive surgical techniques, expanding use of telemedicine for remote patient monitoring and consultations, rising demand for personalized treatment approaches, development of innovative implantable devices with enhanced functionality and longevity, integration of artificial intelligence and machine learning in diagnostic and therapeutic processes.

The growing prevalence of maternal diabetes is expected to drive the expansion of the congenital heart disease (CHD) market in the future. Maternal diabetes, also known as gestational diabetes mellitus (GDM), develops during pregnancy in women who did not have diabetes before conceiving. It is primarily caused by lifestyle changes, such as sedentary behavior, poor dietary habits, and rising obesity rates among women of childbearing age. Maternal diabetes can increase the risk of congenital heart disease (CHD) in infants, as elevated blood sugar levels in the mother can disrupt fetal heart development. The high glucose levels affect the normal formation of the baby's heart, leading to a higher likelihood of CHD. For example, in October 2023, the National Health Service, a UK government agency, reported that adverse pregnancy outcomes for women diagnosed with type 2 diabetes increased from 4.9% in 2021 to 6.6% in 2022. As a result, the rising number of maternal diabetes cases is contributing to the growth of the congenital heart disease (CHD) market.

Key players in the congenital heart disease market are innovating non-surgical heart valves to enhance patient outcomes and quality of life. Non-surgical heart valves, also known as transcatheters, are medical devices treating heart valve diseases without conventional open-heart surgery. For instance, in February 2023, Medtronic, a US-based medical technology company, reintroduced its Harmony Transcatheter Pulmonary Valve (TPV) System. This system, a minimally invasive alternative to open-heart surgery, addresses patients with congenital heart disease, particularly those with native or surgically repaired right ventricular outflow tract (RVOT) anomalies. It stands as the first FDA-approved valve designed for the right side, offering a non-surgical solution for severe pulmonary valve regurgitation patients. The Harmony TPV System received U.S. FDA approval in 2021 and was reintroduced following a voluntary recall, underscoring Medtronic's dedication to advancing solutions for congenital heart disease patients.

In May 2024, Novartis Healthcare Private Limited, a Switzerland-based pharmaceutical company, partnered with Ayala Healthcare Holdings, Inc. (AC Health) to launch an Integrated Cardiovascular and Cancer Care initiative. This collaboration aims to expand access to innovative treatments for breast cancer, heart failure, and high cholesterol. Ayala Healthcare Holdings, Inc. (AC Health) is a Philippines-based pharmaceutical company specializing in generic drugs.

Major companies operating in the congenital heart disease (CHD) market are Pfizer Inc., AstraZeneca Plc, Abbott Laboratories, Novartis AG, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Neusoft Corp., Carestream Health, Midmark Corporation, Contec Medical Systems, Randox Laboratories Ltd., Schiller AG, BPL Medical Technologies, Compumedics Limited, Biocare Medical, Bionet America Inc., Nasan Medical Electronics Pvt Ltd

North America was the largest region in the congenital heart disease (CHD) market in 2024. The regions covered in the congenital heart disease (CHD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the congenital heart disease (CHD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The congenital heart disease (CHD) market consists of revenues earned by entities by providing services such as medical consultations, diagnostic tests, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The congenital heart disease (CHD) market also includes sales of cardiac implants such as pacemakers, implantable cardioverter-defibrillators (ICDs), and ventricular assist devices (VADs). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Congenital Heart Disease (CHD) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on congenital heart disease (chd) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for congenital heart disease (chd) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The congenital heart disease (chd) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Heart Valve Defects; Heart Wall Defects; Blood Vessel Defects; Other Types
• 2) By Diagnosis: Electrocardiogram; Chest X-ray; Echocardiogram; Transesophageal Echocardiogram; Pulse Oximetry; Exercise Stress Test; Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI); Cardiac Catheterization; Other Diagnosis
• 3) By Treatment: Interventional Cardiology; Cardiac Surgery; Telemedicine; Medication Management; Lifestyle Modifications
• 4) By Age Group: Infants; Children; Adolescents; Adults
• 5) By Application: Hospitals And Clinics; Diagnostic Centers; Ambulatory Surgical Centers; Research And Academic Institutions
• Subsegments:
• 1) By Heart Valve Defects: Aortic Valve Stenosis; Pulmonary Valve Stenosis; Mitral Valve Prolapse; Tricuspid Valve Defects; Valve Regurgitation
• 2) By Heart Wall Defects: Atrial Septal Defect (ASD); Ventricular Septal Defect (VSD); Atrioventricular Septal Defect (AVSD); Hypoplastic Left Heart Syndrome (HLHS); Tetralogy of Fallot (TOF)
• 3) By Blood Vessel Defects: Coarctation Of The Aorta; Patent Ductus Arteriosus (PDA); Pulmonary Artery Stenosis; Transposition Of The Great Arteries (TGA); Truncus Arteriosus
• 4) By Other Types: Single Ventricle Defects; Ebstein's Anomaly; Total Anomalous Pulmonary Venous Return (TAPVR); Coronary Artery Anomalies; Pulmonary Venous Obstruction
• Companies Mentioned: Pfizer Inc.; AstraZeneca Plc; Abbott Laboratories; Novartis AG; Medtronic
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Congenital Heart Disease (CHD) Market Characteristics

3. Congenital Heart Disease (CHD) Market Trends And Strategies

4. Congenital Heart Disease (CHD) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Congenital Heart Disease (CHD) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Congenital Heart Disease (CHD) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Congenital Heart Disease (CHD) Market Growth Rate Analysis
• 5.4. Global Congenital Heart Disease (CHD) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Congenital Heart Disease (CHD) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Congenital Heart Disease (CHD) Total Addressable Market (TAM)

6. Congenital Heart Disease (CHD) Market Segmentation

• 6.1. Global Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Heart Valve Defects
• Heart Wall Defects
• Blood Vessel Defects
• Other Types
• 6.2. Global Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Electrocardiogram
• Chest X-ray
• Echocardiogram
• Transesophageal Echocardiogram
• Pulse Oximetry
• Exercise Stress Test
• Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI)
• Cardiac Catheterization
• Other Diagnosis
• 6.3. Global Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interventional Cardiology
• Cardiac Surgery
• Telemedicine
• Medication Management
• Lifestyle Modifications
• 6.4. Global Congenital Heart Disease (CHD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Infants
• Children
• Adolescents
• Adults
• 6.5. Global Congenital Heart Disease (CHD) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Diagnostic Centers
• Ambulatory Surgical Centers
• Research And Academic Institutions
• 6.6. Global Congenital Heart Disease (CHD) Market, Sub-Segmentation Of Heart Valve Defects, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aortic Valve Stenosis
• Pulmonary Valve Stenosis
• Mitral Valve Prolapse
• Tricuspid Valve Defects
• Valve Regurgitation
• 6.7. Global Congenital Heart Disease (CHD) Market, Sub-Segmentation Of Heart Wall Defects, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atrial Septal Defect (ASD)
• Ventricular Septal Defect (VSD)
• Atrioventricular Septal Defect (AVSD)
• Hypoplastic Left Heart Syndrome (HLHS)
• Tetralogy of Fallot (TOF)
• 6.8. Global Congenital Heart Disease (CHD) Market, Sub-Segmentation Of Blood Vessel Defects, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Coarctation Of The Aorta
• Patent Ductus Arteriosus (PDA)
• Pulmonary Artery Stenosis
• Transposition Of The Great Arteries (TGA)
• Truncus Arteriosus
• 6.9. Global Congenital Heart Disease (CHD) Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single Ventricle Defects
• Ebstein's Anomaly
• Total Anomalous Pulmonary Venous Return (TAPVR)
• Coronary Artery Anomalies
• Pulmonary Venous Obstruction

7. Congenital Heart Disease (CHD) Market Regional And Country Analysis

• 7.1. Global Congenital Heart Disease (CHD) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Congenital Heart Disease (CHD) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Congenital Heart Disease (CHD) Market

• 8.1. Asia-Pacific Congenital Heart Disease (CHD) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Congenital Heart Disease (CHD) Market

• 9.1. China Congenital Heart Disease (CHD) Market Overview
• 9.2. China Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Congenital Heart Disease (CHD) Market

• 10.1. India Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Congenital Heart Disease (CHD) Market

• 11.1. Japan Congenital Heart Disease (CHD) Market Overview
• 11.2. Japan Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Congenital Heart Disease (CHD) Market

• 12.1. Australia Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Congenital Heart Disease (CHD) Market

• 13.1. Indonesia Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Congenital Heart Disease (CHD) Market

• 14.1. South Korea Congenital Heart Disease (CHD) Market Overview
• 14.2. South Korea Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Congenital Heart Disease (CHD) Market

• 15.1. Western Europe Congenital Heart Disease (CHD) Market Overview
• 15.2. Western Europe Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Congenital Heart Disease (CHD) Market

• 16.1. UK Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Congenital Heart Disease (CHD) Market

• 17.1. Germany Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Congenital Heart Disease (CHD) Market

• 18.1. France Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Congenital Heart Disease (CHD) Market

• 19.1. Italy Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Congenital Heart Disease (CHD) Market

• 20.1. Spain Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Congenital Heart Disease (CHD) Market

• 21.1. Eastern Europe Congenital Heart Disease (CHD) Market Overview
• 21.2. Eastern Europe Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Congenital Heart Disease (CHD) Market

• 22.1. Russia Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Congenital Heart Disease (CHD) Market

• 23.1. North America Congenital Heart Disease (CHD) Market Overview
• 23.2. North America Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Congenital Heart Disease (CHD) Market

• 24.1. USA Congenital Heart Disease (CHD) Market Overview
• 24.2. USA Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Congenital Heart Disease (CHD) Market

• 25.1. Canada Congenital Heart Disease (CHD) Market Overview
• 25.2. Canada Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Congenital Heart Disease (CHD) Market

• 26.1. South America Congenital Heart Disease (CHD) Market Overview
• 26.2. South America Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Congenital Heart Disease (CHD) Market

• 27.1. Brazil Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Congenital Heart Disease (CHD) Market

• 28.1. Middle East Congenital Heart Disease (CHD) Market Overview
• 28.2. Middle East Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Congenital Heart Disease (CHD) Market

• 29.1. Africa Congenital Heart Disease (CHD) Market Overview
• 29.2. Africa Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Congenital Heart Disease (CHD) Market Competitive Landscape And Company Profiles

• 30.1. Congenital Heart Disease (CHD) Market Competitive Landscape
• 30.2. Congenital Heart Disease (CHD) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Medtronic Overview, Products and Services, Strategy and Financial Analysis

31. Congenital Heart Disease (CHD) Market Other Major And Innovative Companies

• 31.1. Siemens Healthineers
• 31.2. Philips Healthcare
• 31.3. Roche Diagnostics International Ltd.
• 31.4. Boston Scientific Corp.
• 31.5. Laboratory Corporation of America Holdings (LabCorp)
• 31.6. Terumo Corporation
• 31.7. Mindray Medical International Limited
• 31.8. Canon Medical Systems Corporation
• 31.9. Masimo Corporation
• 31.10. Neusoft Corp.
• 31.11. Carestream Health
• 31.12. Midmark Corporation
• 31.13. Contec Medical Systems
• 31.14. Randox Laboratories Ltd.
• 31.15. Schiller AG

32. Global Congenital Heart Disease (CHD) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Congenital Heart Disease (CHD) Market

34. Recent Developments In The Congenital Heart Disease (CHD) Market

35. Congenital Heart Disease (CHD) Market High Potential Countries, Segments and Strategies

• 35.1 Congenital Heart Disease (CHD) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Congenital Heart Disease (CHD) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Congenital Heart Disease (CHD) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer